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Abstract 26 
 27 
Background The HOX genes are a family of homeodomain-containing transcription 28 
factors that determine cellular identity during development and which are dys-29 
regulated in some cancers. In this study we examined the expression and oncogenic 30 
function of HOX genes in mesothelioma, a cancer arising from the pleura or 31 
peritoneum which is associated with exposure to asbestos. 32 
Methods We tested the sensitivity of the mesothelioma-derived lines MSTO-211H, 33 
NCI-H28, NCI-H2052, and NCI-H226 to HXR9, a peptide antagonist of HOX protein 34 
binding to its PBX co-factor. Apoptosis was measured using a FACS-based assay 35 
with Annexin, and HOX gene expression profiles were established using RT-QPCR 36 
on RNA extracted from cell lines and primary mesotheliomas. The in vivo efficacy of 37 
HXR9 was tested in a mouse MSTO-211H flank tumor xenograft model. 38 
Results We show that HOX genes are significantly dysregulated in malignant 39 
mesothelioma. Targeting HOX genes with HXR9 caused apoptotic cell death in all of 40 
the mesothelioma-derived cell lines, and prevented the growth of mesothelioma 41 
tumors in a mouse xenograft model. Furthermore, the sensitivity of these lines to 42 
HXR9 correlated with the relative expression of HOX genes that have either an 43 
oncogenic or tumor suppressive function in cancer. The analysis of HOX expression 44 
in primary mesothelioma tumors indicated that these cells could also be sensitive to 45 
the disruption of HOX activity by HXR9, and that the expression of HOXB4 is 46 
strongly associated with overall survival. 47 
Conclusion HOX genes are a potential therapeutic target in mesothelioma, and 48 
HOXB4 expression correlates with overall survival.  49 
 50 
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 51 
Background 52 
 53 
The HOX genes are a family of transcription factors characterized by highly 54 
conserved DNA- and co-factor binding domains. This conservation has been driven 55 
by their roles in some of the most fundamental patterning events that underlie early 56 
development[1]. Most notable of these is the patterning of the anterior to posterior 57 
axis, for which a precise spatial and temporal order in the expression of HOX genes is 58 
required. This is achieved in part through a chromosomal arrangement whereby HOX 59 
genes are present in closely linked clusters allowing the sharing of common enhancer 60 
regions. In mammals there are four such clusters (A-D), containing a total of 39 HOX 61 
genes[1]. The relative position of each HOX gene 3’ to 5’ within the cluster is 62 
reflected in a number of key attributes, including the spatial and temporal order of 63 
expression, whereby the 3’ most genes are expressed earlier than their 5’ neighbors. 64 
The nomenclature of the HOX genes reflects this precise chromosomal ordering, with 65 
members of each cluster being numbered with respect to the 3’ end, thus for example, 66 
the 3’ most member of cluster B is HOXB1[2]. 67 
 68 
The 3’ to 5’ order of HOX genes is reflected not only in their expression patterns but 69 
also in their DNA binding specificities and co-factor interactions. For example, the 70 
products of the 3’ HOX genes (1 to 9) bind to another transcription factor, PBX, 71 
which modifies their binding specificity to DNA[3], influences their 72 
nucleocytoplasmic distribution[3], and also determines whether a HOX protein will 73 
activate of repress transcription of downstream target genes[4]. This interaction with 74 
PBX is mediated through a highly conserved hexapeptide region on HOX proteins 1-9 75 
 3 
that binds to a cleft in PBX[3, 5]. Once PBX has bound it can recruit other specific 76 
co-factors, including MEIS, which can then further modify HOX activity[6]. 77 
 78 
Although HOX genes were initially characterized as key developmental genes, they 79 
also function in adult stem cells to promote proliferation[7], and subsequently in their 80 
progeny to confer lineage-specific identities[8]. Furthermore, HOX genes are strongly 81 
dys-regulated in cancer, and generally exhibit greatly increased expression. This 82 
differential change in expression in cancer may reflect the apparent ability of some 83 
HOX genes to function as tumor suppressors and some as oncogenes. Thus for 84 
example, HOXA5 acts as a tumor suppressor in breast cancer by stabilizing P53[9], 85 
whilst forced expression of HOXB6 can immortalize fibroblast cells[10]. Further 86 
examples of this phenomenon are listed in Table 1. 87 
 88 
The dys-regulation of HOX genes has been demonstrated in a range of cancers, and in 89 
some it has been shown to be a potential therapeutic target through the use of a 90 
peptide, HXR9. HXR9 prevents PBX binding to HOX and triggers apoptosis in 91 
malignant cells, whilst sparing normal adult cells[11-17]. Although these studies 92 
include non-small cell lung cancer (NSCLC)[16], they do not encompass 93 
mesothelioma, a malignancy of the mesothelium cells which is most frequently found 94 
in the lung and is associated with long term exposure to asbestos[18]. Mesothelioma 95 
has limited treatment options and generally a very poor prognosis[18], and therefore 96 
finding novel therapeutic approaches in this disease is an important goal. In this study 97 
we show that HOX dys-regulation is present in cell lines derived from mesothelioma, 98 
and in primary tumors, usually with a significant increase in the expression of those 99 
HOX genes that behave as oncogenes. Furthermore, antagonism of the HOX / PBX 100 
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interaction in these cell lines triggers apoptosis, with malignant cells generally being 101 
considerably more sensitive to HXR9 than cells derived from non-malignant 102 
mesothelium cells. 103 
 104 
Materials and Methods 105 
 106 
Cell lines and culture 107 
The cell lines used in this study are listed in Table 2. They were obtained from the 108 
ATCC through LGC Standards Ltd (UK), and were cultured according to the 109 
instructions on the LGC Standards website. 110 
 111 
Synthesis of HXR9 and CXR9 peptides 112 
HXR9 is an 18 amino acid peptide consisting of the previously identified hexapeptide 113 
sequence that can bind to PBX and nine C-terminal arginine residues (R9) that 114 
facilitate cell entry. The N-terminal and C-terminal amino bonds are in the D-isomer 115 
conformation, which has previously been shown to extend the half-life of the peptide 116 
to 12 hours in human serum[14]. CXR9 is a control peptide that lacks a functional 117 
hexapeptide sequence but which includes the R9 sequence. The sequences of these 118 
peptides have been published previously[13]. All peptides were synthesized using 119 
conventional column based chemistry and purified to at least 80% (Biosynthesis Inc., 120 
USA). 121 
 122 
Imaging of cell cultures 123 
 5 
Cells were plated in 6-well plates using 2 ml of medium and allowed to recover for at 124 
least 24 hours.  When approximately 60% confluent, cells were treated with the active 125 
peptide HXR9 (60 µM) or the control peptide CXR9 (60 µM) for 3 hours.     126 
 127 
Immunohistochemistry for HOXA4, HOXA9, and HOXB4 128 
Expression of HOXA4, HOXA9, and HOXB4 in mesothelioma and normal 129 
mesothelium tissue was investigated using 3 µm-thick, formalin fixed, paraffin 130 
embedded tissue array sections (MS081, US Biomax, Rockville, MD, USA). 131 
Immunohistochemical analysis was performed using a monoclonal rabbit anti-132 
HOXB4 antibody (ab676093, 1:100 dilution, Abcam, Cambridge, UK), a polyclonal 133 
rabbit anti-HOXA4 antibody (ab131049, 1:500 dilution, Abcam, Cambridge, UK), 134 
and a polyclonal rabbit anti-HOXA9 antibody (ab191178, 1:75 dilution, Abcam, 135 
Cambridge, UK). The ABC detection method with peroxidase block 136 
(DakoCytomation) was used for all of these primary antibodies. Antigen retrieval was 137 
performed using pH 9.0 Tris/EDTA buffer (DakoCytomation) and heating in a 138 
microwave for 23 minutes. 139 
 140 
Analysis of cell death and apoptosis 141 
Cells were treated with HXR9 or CXR9 as described above.  Cell viability was 142 
assessed using the MTS assay (Promega) according to the manufacturer’s 143 
instructions.  Cells were harvested by incubating in trypsin-EDTA (Sigma) at 37ºC 144 
until detached and dissociated.  Apoptotic cells were identified using flow cytometry 145 
(Beckman Coulter Epics XL Flow) and the Annexin V-PE apoptosis detection kit (BD 146 
Pharmingen) as described by the manufacturer’s protocol. Caspase-3 activity was 147 
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measured using the EnzCheck Caspase-3 Assay Kit (Molecular Probes), using the 148 
protocol defined by the manufacturer. 149 
 150 
RNA purification and reverse transcription 151 
Total RNA was isolated from cells using the RNeasy Plus Mini Kit (Qiagen) by 152 
following the manufacturer’s protocol.  The RNA was denatured by heating to 65ºC 153 
for 5 minutes.  cDNA was synthesized from RNA using the Cloned AMV First Strand 154 
Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. 155 
 156 
Quantitative PCR 157 
Quantitative PCR was performed using the Stratagene MX3005P real-time PCR 158 
machine and the Brilliant SYBR Green QPCR Master Mix (Stratagene).  The 159 
following primers were designed to facilitate the unique amplification of β-actin, c-160 
Fos, and each HOX gene: 161 
HsBeta-ActinF: 5’ ATGTACCCTGGCATTGCCGAC 3’ 162 
HsBeta-ActinR: 5’ GACTCGTCATACTCCTGCTTG 3’ 163 
HscFos1F: 5’ CCAACCTGCTGAAGGAGAAG 3’ 164 
HscFos1R: 5’ GCTGCTGATGCTCTTGACAG 3’ 165 
HsHOXA1F: 5’ CTGGCCCTGGCTACGTATAA 3’ 166 
HsHOXA1R: 5’ TCCAACTTTCCCTGTTTTGG 3’ 167 
HsHOXA4F: 5’ CCCTGGATGAAGAAGATCCA 3’ 168 
HsHOXA4R: 5’ AATTGGAGGATCGCATCTTG 3’ 169 
HsHOXA5F: 5’ CCGGAGAATGAAGTGGAAAA 3’ 170 
HsHOXA5R: 5’ ACGAGAACAGGGCTTCTTCA 3’ 171 
HsHOXA9F: 5’ AATAACCCAGCAGCCAACTG 3’ 172 
HsHOXA9R: 5’ ATTTTCATCCTGCGGTTCTG 3’ 173 
HsHOXB3F: 5’ TATGGCCTCAACCACCTTTC 3’ 174 
HsHOXB3R: 5’ AAGCCTGGGTACCACCTTCT 3’  175 
HsHOXB4F: 5’ TCTTGGAGCTGGAGAAGGAA 3’ 176 
HsHOXB4R: 5’ GTTGGGCAACTTGTGGTCTT 3’ 177 
HsHOXB5F: 5’ AAGGCCTGGTCTGGGAGTAT 3’ 178 
HsHOXB5R: 5’ GCATCCACTCGCTCACTACA 3’ 179 
HsHOXB6F: 5’ ATTTCCTTCTGGCCCTCACT 3’ 180 
HsHOXB6R: 5’ GGAAGGTGGAGTTCACGAAA 3’ 181 
HsHOXB9F: 5’ TAATCAAAGACCCGGCTACG 3’ 182 
HsHOXB9R: 5’ CTACGGTCCCTGGTGAGGTA 3’ 183 
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HsHOXC4F: 5’ CGCTCGAGGACAGCCTATAC 3’ 184 
HsHOXC4R: 5’ GCTCTGGGAGTGGTCTTCAG 3’ 185 
HsHOXC8F: 5’ CTCAGGCTACCAGCAGAACC 3’ 186 
HsHOXC8R: 5’ TTGGCGGAGGATTTACAGTC 3’ 187 
 188 
Mice and in vivo trial 189 
All animal experiments were conducted in accordance with the United Kingdom Co-190 
ordinating Committee on Cancer Research (UKCCCR) guidelines for the Welfare of 191 
Animals in Experimental Neoplasia and were approved by the University of Surrey 192 
Research Ethics Committee. The mice were kept in positive pressure isolators in 12 193 
hour light / dark cycles and food and water were available ad libitum. 194 
Athymic nude mice were inoculated subcutaneously with a suspension of 2.5 195 
× 106 MSTO-211H cells in culture media (100 µl).  Once tumors reached volumes of 196 
approximately 100 mm3, mice were injected IP with PBS or 25 mg/Kg HXR9 in PBS 197 
(injection volume 100 µl), every 4 days.  The mice were sacrificed after 36 days and 198 
the tumors were excised for RNA extraction, as previously described[12]. Each 199 
treatment group contained 10 mice. The mice were monitored carefully for signs of 200 
distress, including behavioral changes and weight loss.  201 
 202 
Patient characteristics 203 
Primary mesothelioma samples were obtained from 16 male and 5 female patients. 204 
The median patient age at diagnosis was 63.9 years (range, 38.2–79.53 years) and 205 
median survival was 9.04 months (range, 0.23–81.85 months). Recruitment was via a 206 
specialized multidisciplinary thoracic oncology clinic, involving thoracic surgeons, 207 
radiation oncologists, and medical oncologists. Histopathology and imaging review 208 
was undertaken for all patients. Patients underwent tumor resection at the Department 209 
of Thoracic Surgery, Guy’s & St Thomas’ NHS Foundation Trust. Tumor samples 210 
were confirmed as mesothelioma by pathological examination and categorized as a 211 
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sarcomatoid, biphasic, or epithelial type using an antibody panel that included 212 
BerEP4, CEA, TTF1, Calretinin, WT1, CK5, MNF116, and EMA. Tissues and data 213 
were released for study from the KHP Cancer Biobank in accordance with NHS REC 214 
approval number 07/H0804/91.  215 
 216 
Statistical analysis 217 
All values are given as the mean of three independent experiments and error bars 218 
show the standard error of the mean. Categorical variables were compared using 219 
Student’s t-test or a one-way ANOVA. Survival curves were generated using the 220 
Kaplan-Meier method and compared using the log-rank test. A p value <0.05 was 221 
considered to be significant. 222 
 223 
Results 224 
 225 
HOX gene expression in mesothelioma-derived cell lines and primary tumors 226 
In order to assess the expression of HOX genes in mesothelioma we used QPCR to 227 
measure RNA levels in four cell lines derived from this malignancy: NCI-H28, NCI-228 
H2052, NCI-H226, and MSTO-211H, together with Met-5A which is derived from 229 
non-malignant mesothelium cells (Table 2). HOX gene expression was also studied in 230 
primary mesothelioma tumors. The expression of HOX genes within each cell line and 231 
between cell lines varied considerably, with MSTO-211H and Met-5A generally 232 
having far higher expression than the other cell lines. The only HOX genes expressed 233 
uniquely by a single cell line were HOXC12 and HOXD12, in Met-5A. Analysis of 234 
HOX genes that are known to have oncogenic or tumor suppressive functions (Table 235 
1) likewise reveals considerable variation, although Met-5A showed higher 236 
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expression of the potential tumor suppressor genes HOXA4 and HOXA5 compared to 237 
the malignant cell lines (Fig 1a). We also assessed the expression of these HOX genes 238 
in 21 primary tumors using RT-QPCR, as well the protein expression of the three 239 
most strongly expressed, HOXA4, HOXA9, and HOXB4 at the protein level using 240 
immunohistochemistry (Fig 1b).  241 
 242 
High HOXB4 tumor expression is associated with poor overall survival 243 
We looked for associations between the RNA expression levels of the different HOX 244 
genes and patient survival. The tumors of patients surviving less than 6 months had a 245 
significantly higher expression of HOXB4 (p = 0.0166; Fig 1c), and likewise a 246 
Kaplan-Meier analysis of overall survival (OS) showed that high HOXB4 tumor 247 
expression was associated with a significantly shorter OS (p = 0.041; Fig 1d).  248 
 249 
HXR9 is cytotoxic to mesothelioma cells 250 
Given the high level of HOX expression in the mesothelioma cell lines, we treated 251 
cells with the HOX / PBX inhibitor HXR9 that has previously been shown to block 252 
HOX / PBX interactions and trigger apoptosis in a number of other cancers[11-17]. 253 
Use of a fluorescently labeled version of HXR9 demonstrated that it can be taken up 254 
by the cell lines studied here (Fig 2a), and the MTS assay for cell viability revealed 255 
that HXR9 is cytotoxic in all five cell lines (Fig 2b,c; Table 2). The non-malignant 256 
line Met-5A is amongst the least sensitive with an IC50 of 98µM, whilst the NCI-H28 257 
cell line is the most sensitive with an IC50 of 18µM (Fig 2c, Table 2). 258 
 259 
HXR9 triggers apoptosis 260 
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Previous studies have suggested that the mechanism of cell death when HOX function 261 
is blocked by HXR9 is primarily through apoptosis[11-17]. To establish whether this 262 
is also the case of the mesothelioma derived cell lines, a standard FACS based assay 263 
for apoptosis-associated cell membrane changes was used. This involves the use of 264 
Annexin V that binds to membrane components usually located on the cytoplasmic 265 
side but which relocates to the external surface during apoptosis[19], and a 266 
fluorescent dye (7AAD) which binds to DNA but can only enter cells when 267 
membrane integrity has been lost. This assay revealed that all the mesothelioma cell 268 
lines underwent apoptosis when treated with HXR9 at the relevant IC50 (Fig 3), with 269 
the non-malignant cell line Met-5A showing the lowest level of apoptosis and NCI-270 
H2052 the highest (Fig 3c). 271 
 272 
The induction of apoptosis by HXR9 is thought to depend, at least in part, upon a 273 
rapid increase in cFos expression[14], and QPCR analysis of the HXR9 treated cells 274 
correspondingly showed a significant increase in cFos in all of the cell lines, with the 275 
smallest increase in Met-5A and the largest increase in the most sensitive cell line, 276 
NCI-H28 (Fig 4a). Correspondingly NCI-H28 also showed the greatest increase in 277 
Caspase 3 activity (a protease involved in the apoptotic pathway; Fig 4b), whilst Met-278 
5A failed to show any significant increase in caspase activity (Fig 4c). 279 
 280 
Sensitivity to HXR9 correlates with the expression of specific HOX genes 281 
The expression of HOX genes with previously identified oncogenic or tumor 282 
suppressor properties (Table 1; Fig 1), raises the possibility that the expression profile 283 
of these genes could determine the sensitivity of cells to HXR9. To assess this we 284 
divided HOX genes into two groups – those with potential oncogenic functions, and 285 
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those with possible tumor suppressor functions. An expression ratio was obtained by 286 
dividing the total expression of genes in the former group with that in the latter (‘O/S 287 
ratio’). This revealed that the most sensitive cell line, NCI-H28, has the highest O/S 288 
ratio, whilst Met-5a and the least sensitive malignant line, NCI-H226, have the lowest 289 
O/S ratios (Fig 5a). Plotting these ratios against the IC50 for each cell line suggest a 290 
positive correlation between the O/S ratio and sensitivity (Fig 5b). Furthermore, the 291 
calculated O/S ratios for the primary mesothelium tumors indicate that these cells 292 
could also be sensitive HXR9 (Fig 5b). 293 
 294 
HXR9 blocks the growth of mesothelioma tumors in vivo 295 
In order to determine whether HXR9 could also block tumor growth in vivo, we 296 
established a xenograft mouse flank model using the MSTO-211H cell line. Mice 297 
were injected IP with either PBS or 25 mg/Kg HXR9 in PBS every 4 days after 298 
tumors had grown to a mean volume of 100 mm3. HXR9 significantly retarded tumor 299 
growth compared to PBS alone (Fig 6a). In tumors from mice injected with PBS only, 300 
we found a significant, linear relationship between the expression of HOXB4 and final 301 
tumor size (r2 = 0.8278; p = 0.0321; Fig 6b). 302 
 303 
Discussion 304 
 305 
The dys-regulation of HOX genes in cancer is now well established, and in many 306 
cases a putative function for individual HOX genes has been established[20]. Despite 307 
a high degree of sequence and regulatory conservation between HOX genes, there is 308 
apparently a wide range of cancer specific functions which include both oncogenic 309 
and tumor suppressing activities. Thus for example the fifth gene of the HOXA 310 
 12 
complex, HOXA5, acts primarily as a tumor suppressor in breast cancer through 311 
stabilizing p53[9], whilst its closely related counterpart in the HOXB cluster, HOXB5, 312 
can be defined as an oncogene as it can immortalize fibroblast cells upon 313 
transfection[21]. 314 
 315 
None of these studies have as yet addressed whether HOX genes are dys-regulated in 316 
mesothelioma, but here we show that cell lines derived from mesothelioma as well as 317 
primary mesothelioma cells have distinctly different HOX expression patterns from 318 
the Met-5a cell line that is derived from normal mesothelium. One of the most 319 
striking differences is the expression of HOXC12 and HOXD12 by Met-5a but not by 320 
any of the mesothelioma cell lines. HOXC12 is repressed in follicular lymphoma 321 
through hypermethylation of its promoter, and has also been implicated in the 322 
differentiation of follicle cells[22], both of which suggest a possible function in tumor 323 
suppression. Likewise, the function of HOXD12 has not been defined, but it has been 324 
shown to be silenced in melanoma cells through the methylation of its promoter[23]. 325 
 326 
Another oncogenic HOX gene that we found to be up-regulated in primary 327 
mesothelioma tumors was HOXB4. High HOXB4 expression levels were associated 328 
with shorter OS, suggesting that HOXB4 expression is a potential prognostic factor in 329 
this malignancy. We also found that there was a positive, linear relationship between 330 
HOXB4 expression and tumor growth a mouse model of human mesothelioma. Given 331 
the functional redundancy amongst HOX proteins, this finding that HOXB4 was the 332 
only HOX gene among the 39-strong family to have any prognostic significance 333 
seems unexpected. However, there are a number of other cancers for which a single 334 
HOX gene alone acts as a prognostic marker, and the identity of the HOX gene in each 335 
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case varies from one malignancy to another. Examples include HOXC6 in gastric 336 
cancer, HOXB8 in ovarian cancer, and HOXD3 in breast cancer[24]. This might 337 
reflect the embryonic origins of different cancer types, as HOX gene expression in 338 
adult cells tends to reflect their developmental origin[25]. From a practical view point, 339 
there are currently no reliable markers of OS in mesothelioma[26], and the use of 340 
HOXB4 as a prognostic marker in this context therefore justifies further evaluation. 341 
 342 
In this study we have found that the ratio of expression between HOX genes with a 343 
putative oncogenic function and those that have tumor suppressor activity (‘O/S 344 
ratio’) predicts which mesothelioma cell lines are most sensitive to HXR9, a peptide 345 
that prevents HOX proteins binding to PBX and has been shown to cause apoptosis in 346 
other malignancies[11-17]. The O/S ratio may indicate the degree to which malignant 347 
cells are dependent on the activity of oncogenic HOX genes for their proliferation and 348 
survival, a concept similar to the idea of ‘oncogene addiction’[27], which would 349 
explain their sensitivity to HXR9. The extent to which this is true is yet to be 350 
determined, but at a more practical level the O/S ratio might act as a biomarker for the 351 
sensitivity of mesothelioma cells to HXR9, and could ultimately be used to select 352 
patients that might benefit from this therapeutic approach. 353 
 354 
 355 
Competing interests 356 
The authors declare that they have no competing interests 357 
 358 
Authors’ contributions 359 
 14 
RM designed and oversaw the study and wrote the manuscript draft. GS conducted 360 
the in vivo study. CG oversaw the collection of tumour samples (London) and helped 361 
analyse the data. ZT oversaw the collection of tumour samples (Cardiff) and helped 362 
analyse the data. JS oversaw the collection of tumour samples (London) and helped 363 
analyse the data. KH helped design the study and write the manuscript. HP helped 364 
design the study, write the manuscript, and analyse the data. 365 
 366 
Acknowledgments 367 
The authors gratefully acknowledge the support of the British Lung Foundation, grant 368 
number ICAPPG10-1. 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
Table 1 HOX genes with potential oncogenic or tumor suppressor functions 379 
 380 
Gene O / S Evidence Reference 
HOXA1 O Transforms non-malignant mammary epithelial cells [28] 
HOXA9 O Key oncogene in leukemia [29] 
HOXB3 O Pro-survival and proliferation gene in leukemia [29] 
HOXB4 O Pro-survival and proliferation gene in leukemia [29] 
HOXB5 O Transfection can immortalize fibroblast cells [21] 
HOXB6 O Transfection can immortalize myelomonocytic cells [10] 
HOXB9 O Promotes tumorogenesis in breast cancer [30] 
HOXC4 O High expression in malignant prostate cells [31] 
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HOXA4 S Blocks spread of ovarian cancer cells [32] 
HOXA5 S Identified as a tumor suppressor gene in breast ca [9] 
HOXC8 S Expression inversely related to progression [33] 
HOXC12 S Promotes cell differentiation in follicular lymphoma [22] 
HOXD12 S Silenced in melanoma cells [23] 
 381 
O, HOX gene with oncogenic activity; S, HOX gene with tumor suppressor activity 382 
 383 
 384 
Table 2 Mesothelioma-derived cell lines used in this study 385 
 386 
Cell 
line 
Source IC50 
HXR9 
(µM) 
Ref 
Met-5a Normal mesothelium cells from pleural fluid 98 [34] 
NCI-
H28 
Pleural effusion 18 ATCC 
MSTO-
211H 
Biphasic mesothelioma (fibroblast morphology) 28 [35] 
NCI-
H2052 
Pleural effusion (epithelial morphology) 45 ATCC 
NCI-
H226 
Squamous carcinoma; mesothelioma (epithelial 
morphology). This cell line was derived from non-
small cell lung cancer, although it was subsequently 
found to have a number of mesothelioma-related 
properties, including the expression of mesothelin. 
107 ATCC, 
[36] 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
Figure legends 397 
 398 
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Figure 1. Expression of HOX genes in cell lines derived from mesothelioma (a) and 399 
(b) primary mesothelioma tumors. These genes were previously shown to function as 400 
either oncogenes or tumor suppressors (see Table 1 for more detail). The relative 401 
levels of RNA for each gene are shown as a ratio with Beta-actin (×10000 for NCI-402 
H28, NCI-H2052 and NCI-H226, ×100 for primary mesothelioma tumors, Met-5A, 403 
and MSTO-211). For the cell lines (a) each value is the mean of three experiments, 404 
and error bars show the SEM. For the primary tumors (b) the expression of each HOX 405 
gene is shown for each individual tumor. The values shown are the mean of three 406 
technical repeats. No error bars are included in order to simplify the figure, although 407 
all repeats were within 10% of the mean value. For three of the HOX genes, 408 
(HOXA4, HOXA9, and HOXB4), the protein expression was also determined using 409 
immunohistochemistry and an example of each staining from a single tumor is shown. 410 
Scale bar: 20 µm. Neg, negative – no primary antibody. (c) HOXB4 tumor expression, 411 
as determined using quantitative real-time PCR, is significantly higher amongst 412 
patients surviving for less than 6 months after diagnosis (values on the y-axis are the 413 
ratio of HOXB4 to Beta-actin expression ×10000). (d) HOXB4 expression is 414 
associated with a shorter overall survival. Kaplan-Meier survival curves for patients 415 
with high- and low-HOXB4 expressing tumors (p = 0.041). The cut-off point between 416 
high- and low-expression was determined as the midpoint between the mean values of 417 
HOXB4 expression shown in (c), which was 53. 418 
 419 
Figure 2. HXR9 is cytotoxic in mesothelioma-derived cell lines. (a) Fluorescent 420 
micrograph of NCI-H28 cells treated with 18µM FITC-HXR9 (green) showing uptake 421 
into the nucleus and cytoplasm. Cell nuclei are stained blue. Scale bar: 5 µm. (b) 422 
Sample dose response curves for HXR9 and CXR9 treatment of NCI-H28 and Met-423 
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5A cell lines. (c) IC50 values for HXR9 in mesothelioma-derived cell lines. All 424 
incubations with HXR9 were for two hours. Each value is the mean of 5 experiments, 425 
error bars show the SEM. The NCI-H28, MSTO-211H, and NCI-H2052 cells were all 426 
significantly more sensitive to killing by HXR9 than Met-5a (**, p < 0.01; ***, p < 427 
0.001). 428 
 429 
Figure 3. HXR9 triggers apoptosis in treated cells. The mechanism of cell death was 430 
analyzed using a FACS-based Annexin / 7AAD method to assess early and late 431 
apoptosis. (a) Sample dot plots for NCI-H28 cells treated with 18 µM HXR9 for two 432 
hours. Viable cells sort to the lower left hand quadrant (low Annexin / 7AAD 433 
staining), whilst cells in early and late apoptosis sort to the lower and upper right hand 434 
quadrants, respectively. Necrotic cells are in the upper left hand quadrant. (b) 435 
Apoptosis in NCI-H28 cells either untreated or incubated with 18 µM HXR9 or 436 
CXR9 for two hours. The values are the means of three experiments, error bars show 437 
the SEM. Treatment with HXR9 causes a significant increase in apoptosis (*, p < 438 
0.05). (c) Summary of apoptosis data for all five cell lines. V – viable cells, EA – cells 439 
in early apoptosis, LA – cells in late apoptosis, N-necrotic cells. The values are the 440 
means of three experiments, error bars show the SEM. ***, p < 0.001; **, p < 0.01 441 
relative to the corresponding values for Met-5a. 442 
 443 
Figure 4. Mechanisms of cell death. (a) Induction of cFos in mesothelioma-derived 444 
cell lines. The amount of cFos RNA was determined by QPCR in cells either 445 
untreated or treated with HXR9 or CXR9 for two hours at the IC50 for each. 446 
Expression is shown relative to Beta-actin (×10000). The values are the means of 447 
three experiments, error bars show the SEM. *** indicates a p < 0.001 compared to 448 
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cFos expression in untreated cells. (b) Caspase 3 activation in NCI-H28 cells and 449 
Met-5A cells (c). The values are the means of three experiments, error bars show the 450 
SEM. * indicates a p < 0.05 compared to caspase 3 activity in untreated cells. 451 
 452 
Figure 5. (a) Ratios of oncogenic to tumor suppressor HOX gene expression (O/S 453 
ratio) in mesothelioma derived cell lines. The values are the means of three 454 
experiments, error bars show the SEM. *** denotes p < 0.001 compared to the O/S 455 
ratio in the non-malignant mesothelium cell line Met-5A; (+) denotes that no 456 
expression of tumor suppressor HOX genes was detected in NCI-H28 so the ratio 457 
could not be calculated. (b) Correlation between sensitivity to HXR9 and O/S ratio. 458 
The IC50 for killing by HXR9 is plotted against the O/S ratio for each cell line (black 459 
dots), revealing a possible negative correlation between the two. This relationship can 460 
be modeled using a third order polynomial equation (r2 = 1), which is shown as a solid 461 
black line. The O/S ratio of each primary tumor was used to calculate its predicted 462 
sensitivity to HXR9 (red dots). 463 
 464 
Figure 6. HXR9 blocks the growth of mesothelioma tumors in vivo. (a) The growth of 465 
MSTO-211H tumors in xenograft mice injected IP every 4 days with PBS or 25 466 
mg/Kg HXR9, for a total of 5 times. P values were calculated using a Student’s t-test 467 
for each time point, “*” indicates statistical significance (p = 0.008, p = 0.037, and p = 468 
0.041 for days 30, 34, and 37, respectively. (b) HOXB4 expression in the excised 469 
tumors from PBS-treated mice, as determined by QRT-PCR. There was a linear 470 
relationship between tumor size and HOXB4 expression (r2 = 0.8278; p = 0.0321).   471 
 472 
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